European biomedical innovation has left the building (much like Elvis)…

Posted by:

European Court Bans Patents Based on Embryonic Stem Cells.

Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University of Bonn, Germany, who had a patent on a method for generating neurons from human embryonic stem cells rejected by the court, called the ruling “the worst possible outcome”, and “a disaster for Europe”.

He and other scientists worry that the ruling will cause European companies and scientists to miss out on commercial applications for embryonic-stem-cell research.

Continue Reading →
0

World’s first malaria vaccine works in major trial

Posted by:

Using IPRs effectively in neglected diseases R&D – What lessons can be learned from the positive results of the GSK and PATH’s Malaria Vaccine Initiative? Allowing partners which contribute proprietary technologies to maintain ownership and income from the end product may be key to achieving tangible results like those of the MVI. In this case, GSK, owner of many of the essential technologies of the vaccine, will supply the final product at a preferred price (cost+5%).This hybrid approach can support ...

Continue Reading →
0

Patently engaged – Microsoft vs. Google – a commercial clash or a philosophical one?

Posted by:

The dispute between Microsoft and Google over the Android operating system appears to have entered a new phase. Microsoft is reported to have signed licensing deals with 10 manufacturers who now pay a user fee for every smartphone and/or table that is sold. Google disputes the validity of Microsoft’s claims and the patents that underpin it.

The broader question remains whether or not these disputes are solely based on legal and commercial grounds, or are they part of a deeper philosophical ...

Continue Reading →
0
Page 15 of 15 «...101112131415